iBio (IBIO) Competitors

X4 Pharmaceuticals (NASDAQ:XFOR) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings.

Is XFOR or IBIO more profitable?

iBio's return on equity of -73.15% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	N/A	-236.19%	-75.14%
iBio	N/A	-73.15%	-45.51%

Which has stronger valuation & earnings, XFOR or IBIO?

iBio has lower revenue, but higher earnings than X4 Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$2.56M	254.69	-$101.17M	-$0.19	-19.74
iBio	$375K	27.12	-$24.91M	N/A	N/A

Which has more volatility & risk, XFOR or IBIO?

X4 Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Do analysts rate XFOR or IBIO?

X4 Pharmaceuticals presently has a consensus price target of $85.00, indicating a potential upside of 2,166.67%. iBio has a consensus price target of $4.30, indicating a potential upside of 317.48%. Given X4 Pharmaceuticals' higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
iBio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of XFOR or IBIO?

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.6% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer XFOR or IBIO?

In the previous week, X4 Pharmaceuticals had 11 more articles in the media than iBio. MarketBeat recorded 14 mentions for X4 Pharmaceuticals and 3 mentions for iBio. iBio's average media sentiment score of 0.67 beat X4 Pharmaceuticals' score of -0.06 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor XFOR or IBIO?

X4 Pharmaceuticals received 76 more outperform votes than iBio when rated by MarketBeat users. Likewise, 68.10% of users gave X4 Pharmaceuticals an outperform vote while only 37.50% of users gave iBio an outperform vote.

Company	Underperform	Outperform
X4 Pharmaceuticals	Outperform Votes 79 68.10%	Underperform Votes 37 31.90%
iBio	Outperform Votes 3 37.50%	Underperform Votes 5 62.50%

Summary

X4 Pharmaceuticals beats iBio on 9 of the 14 factors compared between the two stocks.